This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joosten, S. A. Articles by Paul, L. C. Search for Related Content PubMed PubMed Citation Articles by Joosten, S. A. Articles by Paul, L. C.

(American Journal of Pathology. 2002;160:1301-1310.)
© 2002 American Society for Investigative Pathology

Regular Articles

Antibody Response Against Perlecan and Collagen Types IV and VI in Chronic Renal Allograft Rejection in the Rat

Simone A. Joosten^*, Mieneke G. A. van Dixhoorn^*, Maria C. Borrias^*, Hallgrimur Benediktsson, Peter A. van Veelen, Cees van Kooten^* and Leendert C. Paul^*

From the Departments of Nephrology^* andImmunohematology and Blood Transfusion,Leiden University Medical Center, Leiden, The Netherlands; and theDepartment of Pathology and LaboratoryMedicine, University of Calgary, Calgary,Alberta, Canada

Chronic rejection is the leading cause of late renal transplant failure. Various structural lesions are observed in grafts undergoing chronic rejection including glomerular basement membrane (GBM) duplications. The well-established Fisher (F344) to Lewis (LEW) rat renal transplant model for chronic rejection was used to assess the presence and role of the humoral immune response against graft antigens during chronic rejection. LEW recipients of F344 allografts develop transplant glomerulopathy and produce IgG1 antibodies directed against F344 GBM preparations that are detectable 3 weeks after transplantation. Glomerular IgG1 deposition was observed that in vitro co-localized with a rabbit anti-rat GBM antiserum in rejecting F344 grafts; elution experiments of isolated glomeruli yielded IgG1 antibodies reactive in vitro with F344 GBM, but not LEW GBM. Prevention of acute rejection by transient treatment of the recipients with cyclosporin A completely abrogated the production of anti-GBM antibodies. Using proteomic techniques we identified the antigens recognized by the LEW posttransplant sera as being the heparan sulfate proteoglycan perlecan and the 1 chain of collagen type VI in association with the 5 chain of collagen type IV. In conclusion, LEW recipients of F344 kidney grafts produce IgG1 antibodies against donor type perlecan and 1(VI)/5(IV) collagen and develop transplant glomerulopathy. These data implicate an important role for the humoral immune response in the development of glomerulopathy during chronic rejection.

This article has been cited by other articles:

				A. M. Jevnikar and R. B. Mannon Late Kidney Allograft Loss: What We Know about It, and What We Can Do about It Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S56 - S67. [Abstract] [Full Text] [PDF]

				K. J. Tinckam and A. Chandraker Mechanisms and Role of HLA and non-HLA Alloantibodies Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 404 - 414. [Abstract] [Full Text] [PDF]

				S. A. Joosten, V. van Ham, M. C. Borrias, C. van Kooten, and L. C. Paul Antibodies against mesangial cells in a rat model of chronic renal allograft rejection Nephrol. Dial. Transplant., April 1, 2005; 20(4): 692 - 698. [Abstract] [Full Text] [PDF]

				S. A. Joosten, V. van Ham, C. E. Nolan, M. C. Borrias, A. G. Jardine, P. G. Shiels, C. van Kooten, and L. C. Paul Telomere Shortening and Cellular Senescence in a Model of Chronic Renal Allograft Rejection Am. J. Pathol., April 1, 2003; 162(4): 1305 - 1312. [Abstract] [Full Text] [PDF]